2.01
0.06 (3.08%)
| Previous Close | 1.95 |
| Open | 1.96 |
| Volume | 3,029,167 |
| Avg. Volume (3M) | 1,077,388 |
| Market Cap | 768,412,992 |
| Price / Sales | 6.93 |
| Price / Book | 0.710 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2025 - 3 Mar 2025 |
| Profit Margin | -56.43% |
| Operating Margin (TTM) | -54.08% |
| Diluted EPS (TTM) | -0.120 |
| Quarterly Revenue Growth (YOY) | 46.00% |
| Total Debt/Equity (MRQ) | 0.19% |
| Current Ratio (MRQ) | 28.29 |
| Operating Cash Flow (TTM) | 16.17 M |
| Levered Free Cash Flow (TTM) | -30.52 M |
| Return on Assets (TTM) | -3.73% |
| Return on Equity (TTM) | -5.29% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Cronos Group Inc. Common Share | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.83 |
|
Cronos Group, headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the US, the company has an option to acquire 5.9% of US multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 46.40% |
| % Held by Institutions | 15.62% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Timelo Investment Management Inc. | 30 Sep 2024 | 754,803 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Nov 2024 | Announcement | Cronos Group Reports 2024 Third Quarter Results |
| 29 Oct 2024 | Announcement | Cronos Group Inc. to Hold 2024 Third Quarter Earnings Conference Call on November 12, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |